Cannabis and sex: can THC and CBD improve our sex life?

The relationship between infection and standard antibiotics

Could CBD work in the battle against resistant bacterial stress? The results from the University of Queensland in Australia recommend that it is possible. However prior to taking a look at the research study in depth, it is useful to comprehend the development of the relationship between germs and antibiotics.

Considering that the advanced discovery of penicillin by Alexander Fleming in 1928, antibiotics have actually been a vital tool in the battle against germs and infections. And although we still use the same tested methods today, germs have actually developed. When exposed to antibiotics, specific germs, fungi and parasites are able to adjust and cancel the efficiency of the drug by developing resistance.

It’s worth explaining that antimicrobial resistance was likely to take place anyhow, as the genetic code for germs changes with time. Nevertheless, it is believed that the overuse of antibiotics is an important factor that speeds up the advancement of resistant stress.

According to the World Health Organization, antimicrobial resistance “is a significantly severe hazard to global public health that requires action in all sectors of government and in society.” This has led scientists to believe outside package by attempting to identify substances that could be helpful in the battle against harmful germs. Among these substances is cannabidiol (CBD), a cannabinoid discovered in Cannabis sativa.

Researchers are trying to find brand-new methods to assault infections and resistant germs.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that CBD works against Gram-positive germs. Stress of Gram-positive germs consist of Staphylococcus aureus (common in skin infections) and Streptococcus pneumoniae (common in bacterial pneumonia).

Dr. Blaskovich presented his findings at an annual conference of the American Society for Microbiology. In vitro samples of both types of gram-positive germs were treated with artificial CBD. The results led Dr. Blaskovich to the conclusion that CBD works at levels similar to those of prescription antibiotics vancomycin and daptomycin. He also discovered that CBD appeared to work against gram-positive stress of resistant germs, which many conventional antibiotics are beginning to stop working.

” In specific, the activity was picked against the resistant stress of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low propensity to cause resistance and was active against MRSA biofilms. “

The group also conducted another research study using topical CBD to treat a skin infection in mice. Again, although the results were positive, CBD did not appear to get rid of the infection, but simply to decrease the variety of bacterial cells.

Could CBD end up being an antibiotic?

While it is simple to hail this work as a considerable development in the antibacterial abilities of CBD, it is too soon to give up on penicillin.

Although it is believed that the efficiency of CBD might come from the way it assaults the biofilm surrounding bacterial cells, the authors are still unsure of the system of action of CBD oceanic. They also did not think twice to explain the shortcomings of the research study. Dr. Blaskovich explained that given that the results are in the preliminary stages, it is far prematurely for individuals to start treating their CBD infections themselves.

The research study was also conducted in vitro (outside the body), and there is a threat that the results of clinical trials will not be the same. A number of substances have actually revealed antibacterial effectiveness in petri dishes, but then stopped working at this crucial phase. It ought to also be discussed that the two studies were performed in collaboration with Botanix Pharmaceuticals Ltd, a pharmaceutical company specializing in topical midnight CBD products.

Nevertheless, this research could be an important advance for CBD and the battle against antimicrobial resistance. CBD continues to have a great safety profile and is ruled out toxic even in big quantities. Thankfully, Dr. Blaskovich and his group strategy to continue their research.

Scroll to top